Simu Thomas

Dr. Simu Thomas

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
ABAnirban Basu
Anirban Basu
STSimu Thomas
Simu Thomas
RCRichard H. Chapman
Richard H. Chapman
JSJason Spangler
Jason Spangler
Manufacturers of orphan drugs face several obstacles in meeting health technology assessment requirements because of poor availability of natural history data, small sample sizes, single-arm trials, and a paucity of established disease-specific endpoints. There is a need for specific considerations and modified approaches in health technology assessments that would account for the challenges in orphan drug development. Multistakeholder collaborations can benefit patients, their families, and the broader society and reduce the inequity faced by patients with rare diseases.

Verified
Journal Article
Open access
PDF file
OBOliver Blandy
Oliver Blandy
PLPierluigi Lembo
Pierluigi Lembo
Rebecca FolorunsoRebecca Folorunso
Rebecca Folorunso
KMKarl-Johan Myren
Karl-Johan Myren
HCHelene Chevrou-Severac
Helene Chevrou-Severac
STSimu Thomas
Simu Thomas
Background: Real-world evidence (RWE) can complement clinical trials to inform health technology assessments (HTAs). This study examined the extent to which RWE is considered in HTAs of non-oncology orphan medicinal products across six agencies globally. Methods: Published European Medicines Agency decisions were reviewed to identify approved non-oncology orphan medicinal products (2018–2023) that included RWE within their submission package, which was anticipated to align with the inclusion of RWE in HTA submissions. Data were extracted from the corresponding HTA reports published by six national agencies (Australia, Canada, France, Germany, Sweden, and the UK). Results: RWE was included in 105 regulatory submissions and 52.6% of the corresponding HTA reports (range: 29.9% [Germany] to 78.8% [Canada]), nearly 90% of which received a positive decision (range: 44.4% [Australia] to 100.0% [Germany]). RWE was derived from a variety of study designs and commonly supported clinical efficacy across many therapeutic areas. Conclusions: RWE commonly supports HTAs of recently approved non-oncology orphan medicinal products, strengthening the evidence base and contributing to demonstration of product value.